Druggable Genome Screens Identify SPP As an Antiviral Host Target for Multiple Flaviviruses

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2025 Feb 19

PMID 39969998

Authors

Wenjie Qiao

Xuping Xie

Pei-Yong Shi

Yaw Shin Ooi

Jan E Carette

Affiliations

Soon will be listed here.

Abstract

Mosquito-borne flaviviruses, such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus, and yellow fever virus, pose significant public health threats globally. Extensive efforts have led to the development of promising highly active compounds against DENV targeting viral non-structural protein 4B (NS4B) protein. However, due to the cocirculation of flaviviruses and to prepare for emerging flaviviruses, there is a need for more broadly acting antivirals. Host-directed therapy where one targets a host factor required for viral replication may be active against multiple viruses that use similar replication strategies. Here, we used a CRISPR-Cas9 library that we designed to target the druggable genome and identified signal peptide peptidase (SPP, encoded by Histocompatibility Minor 13, HM13), as a critical host factor in DENV infection. Genetic knockout or introducing mutations that disrupt the proteolytic activity of SPP markedly reduced the replication of multiple flaviviruses. Although their substrates differ, SPP has structural homology with γ-secretase, which has been pursued as a pharmacological target for Alzheimer's disease. Notably, SPP-targeting compounds exhibited potent anti-DENV activity at low nanomolar concentrations across multiple primary and disease-relevant cell types, acting specifically through SPP inhibition rather than γ-secretase inhibition. Importantly, SPP inhibitors were active at low nanomolar concentrations against flaviviruses other than DENV including ZIKV while DENV NS4B inhibitors lost activity. This study emphasizes the strong potential of SPP as a pan-flaviviral target and provides a framework for identifying host druggable targets to screen for broad-spectrum antivirals.

References

Richards C, Jabs S, Qiao W, Varanese L, Schweizer M, Mosen P . The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection. Science. 2022; 378(6615):eabn5648. PMC: 9547973. DOI: 10.1126/science.abn5648. View

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C . The global distribution and burden of dengue. Nature. 2013; 496(7446):504-7. PMC: 3651993. DOI: 10.1038/nature12060. View

Kaufmann S, Dorhoi A, Hotchkiss R, Bartenschlager R . Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2017; 17(1):35-56. PMC: 7097079. DOI: 10.1038/nrd.2017.162. View

Pfeffer S, Dudek J, Schaffer M, Ng B, Albert S, Plitzko J . Dissecting the molecular organization of the translocon-associated protein complex. Nat Commun. 2017; 8:14516. PMC: 5321747. DOI: 10.1038/ncomms14516. View

De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W . Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998; 391(6665):387-90. DOI: 10.1038/34910. View

Sanson K, Hanna R, Hegde M, Donovan K, Strand C, Sullender M . Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018; 9(1):5416. PMC: 6303322. DOI: 10.1038/s41467-018-07901-8. View

Ohainle M, Balmaseda A, Macalalad A, Tellez Y, Zody M, Saborio S . Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med. 2011; 3(114):114ra128. PMC: 4517192. DOI: 10.1126/scitranslmed.3003084. View

Weihofen A, Lemberg M, Friedmann E, Rueeger H, Schmitz A, Paganetti P . Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. J Biol Chem. 2003; 278(19):16528-33. DOI: 10.1074/jbc.M301372200. View

10.

Bifani A, Chan K, Borrenberghs D, Tan M, Phoo W, Watanabe S . Therapeutics for flaviviral infections. Antiviral Res. 2023; 210:105517. DOI: 10.1016/j.antiviral.2022.105517. View

11.

Ooi Y, Majzoub K, Flynn R, Mata M, Diep J, Li J . An RNA-centric dissection of host complexes controlling flavivirus infection. Nat Microbiol. 2019; 4(12):2369-2382. PMC: 6879806. DOI: 10.1038/s41564-019-0518-2. View

12.

Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf W, Wilky B . Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023; 388(10):898-912. PMC: 11225596. DOI: 10.1056/NEJMoa2210140. View

13.

Mentrup T, Loock A, Fluhrer R, Schroder B . Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets?. Biochim Biophys Acta Mol Cell Res. 2017; 1864(11 Pt B):2169-2182. DOI: 10.1016/j.bbamcr.2017.06.007. View

14.

Chen C, Malchus N, Hehn B, Stelzer W, Avci D, Langosch D . Signal peptide peptidase functions in ERAD to cleave the unfolded protein response regulator XBP1u. EMBO J. 2014; 33(21):2492-506. PMC: 4283407. DOI: 10.15252/embj.201488208. View

15.

Li Y, Muffat J, Omer Javed A, Keys H, Lungjangwa T, Bosch I . Genome-wide CRISPR screen for Zika virus resistance in human neural cells. Proc Natl Acad Sci U S A. 2019; 116(19):9527-9532. PMC: 6510995. DOI: 10.1073/pnas.1900867116. View

16.

Svedruzic Z, Vrbnjak K, Martinovic M, Miletic V . Structural Analysis of the Simultaneous Activation and Inhibition of γ-Secretase Activity in the Development of Drugs for Alzheimer's Disease. Pharmaceutics. 2021; 13(4). PMC: 8068388. DOI: 10.3390/pharmaceutics13040514. View

17.

Shivaprasad S, Qiao W, Weng K, Umashankar P, Carette J, Sarnow P . CRISPR Screen Reveals PACT as a Pro-Viral Factor for Dengue Viral Replication. Viruses. 2024; 16(5). PMC: 11125577. DOI: 10.3390/v16050725. View

18.

Hoffmann H, Sanchez-Rivera F, Schneider W, Luna J, Soto-Feliciano Y, Ashbrook A . Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host Microbe. 2020; 29(2):267-280.e5. PMC: 7833927. DOI: 10.1016/j.chom.2020.12.009. View

19.

Doody R, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013; 369(4):341-50. DOI: 10.1056/NEJMoa1210951. View

20.

Arnold J, Sharma S, Feng J, Ray A, Smidansky E, Kireeva M . Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog. 2012; 8(11):e1003030. PMC: 3499576. DOI: 10.1371/journal.ppat.1003030. View